American National Bank & Trust’s Teva Pharmaceuticals TEVA Stock Holding History

American National Bank & Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,000	Closed	-$24K	–	217
2018 Q2	$24K	Hold	1,000	–	–	0.01%	188
2018 Q1	$17K	Buy	+1,000	New	+$19.5K	﹤0.01%	207
2015 Q4	–	Sell	-63	Closed	-$4K	–	248
2015 Q3	$4K	Hold	63	–	–	﹤0.01%	230
2015 Q2	$4K	Hold	63	–	–	﹤0.01%	261
2015 Q1	$4K	Hold	63	–	–	﹤0.01%	248
2014 Q4	$4K	Hold	63	–	–	﹤0.01%	251
2014 Q3	$3K	Buy	+63	New	+$3.34K	﹤0.01%	268

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

American National Bank & Trust's TEVA Position: Q3 2018 in Review

American National Bank & Trust sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 1,000 shares — an estimated $24K sold.

American National Bank & Trust first reported a position in TEVA in Q3 2014 and held it in 7 quarters. The position peaked at $24K in Q2 2018. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

American National Bank & Trust reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
American National Bank & Trust sold 1,000 Teva Pharmaceuticals shares in Q3 2018, an estimated $24K.
American National Bank & Trust first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 7 quarters.
American National Bank & Trust's Teva Pharmaceuticals position peaked at $24K in Q2 2018.
557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on American National Bank & Trust's 13F filing for Q3 2018, filed 4 Oct 2018.